HomeNewsQbrexza Now Obtainable for the Therapy of Major Axillary Hyperhidrosis
Posted in News on 2nd October 2018
Qbrexza is supplied as a single-use cloth pre-moistened with 2.4% glycopyrronium solution.

Qbrexza is supplied as a single-use cloth pre-moistened with 2.4% glycopyrronium solution.

Qbrexza (glycopyrronium; Dermira) has been made available for the treatment of primary axillary hyperhidrosis in adults and pediatric patients ≥9 years old.

Qbrexza is supplied as a single-use cloth pre-moistened with 2.4% glycopyrronium solution, an anticholinergic. In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands, reducing sweating. It is intended for topical use in the underarm area only and should not be used more frequently than once every 24 hours.

“People living with primary axillary hyperhidrosis often report feelings of isolation, and struggle in silence for years before finally speaking to a healthcare professional,” said Lisa J. Pieretti, Executive Director for the International Hyperhidrosis Society and a patient advocate for more than 15 years. “The availability of Qbrexza represents an FDA-approved, topical medicine for the millions of adults and children who may be looking for a new way to treat their excessive underarm sweating.”

Each carton of Qbrexza includes 30 pouches. A single cloth should be used to apply Qbrexza to both underarms.

Related Post for New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Botulinum toxin injections present promise to suppress postoperative atrial fibrillation
FDA: Critical Aspect Impact of AML Drug Not Being Acknowledged
New ointment for treating brown recluse spider bites is examined on people
FDA: MS Drug Linked to Circumstances of Stroke, Blood Vessel Wall Tears
New antibody can scale back swelling assaults in sufferers with hereditary angioedema